Purpose: The development of evidence-based guidelines on early pharmacotherapeutic treatment of rheumatoid arthritis (RA) could be useful in Middle Eastern nations striving to improve outcomes in patients with this chronic, debilitating disease. Evidence obtained from local populations should inform such guidelines and therefore our aim was to use real-world data to evaluate the clinical responses of Iraqi patients with RA who received earlier or later treatment with the TNF inhibitor etanercept.
Patients And Methods: Data from patients registered in the Iraq National Center of Rheumatology database from May 2012 to December 2018, inclusive, were analyzed retrospectively. Inclusion criteria were age ≥18 years, meeting the ACR/EULAR 2010 criteria for RA, referral for etanercept treatment, and ≥1 year of follow-up after etanercept initiation. Patients were excluded if they had received another biologic for RA. Included patients were categorized according to two separate stratifications: whether duration of RA symptoms prior to etanercept initiation was ≤10 or >10 years (10 years represented the mean duration for the entire analysis population); and according to whether duration of RA symptoms prior to etanercept initiation was ≤1, >1 to ≤4, >4 to ≤10, >10 to ≤20, or >20 years. The evaluated outcomes were mean change from baseline in Clinical Disease Activity Index (CDAI) and 28-joint Disease Activity Score (DAS28) after 1 year of etanercept treatment.
Results: A total of 979 patients were included. CDAI and DAS28 were significantly reduced (p<0.001 for both) after 1 year of etanercept treatment irrespective of whether duration of RA symptoms prior to treatment was ≤10 or >10 years. Patients with RA symptoms for ≤1 year prior to etanercept initiation showed a significant reduction in CDAI after 1 year of treatment (p=0.01).
Conclusion: Iraqi patients with RA who received earlier treatment with etanercept had superior outcomes compared with those who received later treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064720 | PMC |
| http://dx.doi.org/10.2147/OARRR.S300838 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The relationship between drug-induced immunogenicity and hypersensitivity reactions and skin tests related to infliximab, etanercept and adalimumab in patients with rheumatoid arthritis and ankylosing spondylitis.
Turk J Med Sci
December 2024
Division of Clinical Immunology and Allergy, Department of Chest Diseases, Faculty of Medicine, Ankara University, Ankara, Turkiye.
Background/aim: We aimed to investigate the relationship between serum antidrug antibodies (ADAbs), systemic hypersensitivity, or local injection site reactions to tumor necrosis factor (anti-TNF) drugs and to detect the role of skin tests in the diagnosis of hypersensitivity reactions (HSRs) against anti-TNFs.
Materials And Methods: Sixty-nine ankylosing spondylitis (AS) and 46 rheumatoid arthritis (RA) patients taking infliximab (IFX), adalimumab (ADA), and etanercept (ETN) were enrolled. The demographical data, erythrocyte sedimentation rate (ESR), and c-reactive protein (CRP) levels of the patients were determined, and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) assessment for AS patients and DAS28 (disease activity score) for RA patients were assessed.
Stevens-Johnson syndrome with overlapping features of DRESS syndrome: A report of two cases.
SAGE Open Med Case Rep
December 2024
Division of Dermatology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms are severe cutaneous adverse reactions to drugs that are generally considered distinct entities. In addition to identifying the offending medication, distinguishing between these diagnoses is important, as they have differing treatment regimens and prognoses. Distinction between severe cutaneous adverse reactions, particularly in the early stages of disease, can be difficult, and overlapping conditions have been reported in the literature.
View Article and Find Full Text PDFCase Report: Multi-targeted therapy in the treatment of severe toxic epidermal necrolysis.
Front Pediatr
November 2024
Department of Paediatrics, Queen Elizabeth Hospital, Kowloon, Hong Kong SAR, China.
Article Synopsis
- A 10-year-old boy developed severe toxic epidermal necrolysis due to trimethoprim-sulfamethoxazole and was successfully treated with a multi-targeted therapy approach.
- The treatment team included specialists from pediatrics, dermatology, otolaryngology, urology, wound care, pain management, dietetics, and psychology, demonstrating a comprehensive care model.
- Key interventions included intravenous immunoglobulin, steroids, cyclosporin A for eye issues, amniotic membrane transplantation, and etanercept for steroid management, leading to recovery without side effects by day 13.
Guillain-Barrè syndrome after treatment with anti-tumour necrosis factor α (etanercept) in a rheumatoid arthritis patient: Case report and literature review.
Sci Prog
December 2024
College of Medicine and Health Science, Palestine Polytechnic University, Hebron, State of Palestine.
Rheumatoid arthritis (RA) is often treated with anti-tumor necrosis factor α (anti-TNF-α) medications. While these drugs can cause common side effects such as injection-site and infusion reactions, rare cases of Guillain-Barré syndrome (GBS) have been reported. It's a potentially life-threatening condition characterized by progressive, ascending weakness of the extremities and areflexia, with an incidence of about 1.
View Article and Find Full Text PDFTNF-α inhibitors as therapy for drug-induced severe cutaneous adverse reactions: a case series.
J Dermatolog Treat
December 2024
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Article Synopsis
- - Severe cutaneous adverse reactions (SCARs) like AGEP, DRESS, SJS, and TEN are serious conditions associated with high mortality rates, and while corticosteroids are commonly used for treatment, their effectiveness is uncertain due to infection risks.
- - Recent studies have introduced TNF-α inhibitors, which have shown promise in treating SCARs, with a report indicating that four patients (21-54 years old) treated with these inhibitors had successful recoveries without complications.
- - The TNF-α inhibitors work by targeting the harmful immune response linked to SCARs, but more large-scale trials are needed to confirm their efficacy and ensure a safe approach to their use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!